共 50 条
- [3] Daratumumab in Patients With Bortezomib-Refractory Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits KIDNEY INTERNATIONAL REPORTS, 2021, 6 (08): : 2203 - 2206
- [4] Characteristics of Complement Protein Deposition in Proliferative Glomerulonephritis with Monoclonal Immunoglobulin Deposition CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2023, 18 (12): : 1573 - 1582
- [5] Pregnancy-Associated Proliferative Glomerulonephritis with Monoclonal Immunoglobulin Deposition JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
- [6] Daratumumab for Refractory Proliferative Glomerulonephritis With Monoclonal Immunoglobulin G Deposits and Severe Chronic Kidney Disease CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S215 - S216
- [7] Monoclonal Immunoglobulin Deposition Disease and Proliferative Glomerulonephritis With Monoclonal Immunoglobulin disease- How Do They Differ Clinically? CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E42 - E42
- [8] Proliferative Glomerulonephritis with Monoclonal Immunoglobulin Deposition (PGNMID) Associated with COVID-19 JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 88 - 89